Wellcome Annual Report 2024

The past year marked significant progress in Wellcome's commitment to transformative health advancements through strategic investments and collaborations.

• Financial commitment: In the 2023/24 period, Wellcome invested £1.6 billion in research, focusing on ambitious projects in science, health and wellbeing, while addressing urgent global health challenges.
• Innovative advancements: We celebrated the approval of the first new pharmacological approach for treating schizophrenia in 50 years and the world’s first vaccine for chikungunya. These were realised through strategic partnerships and long-term investments in research.
• Strategic partnerships: We forged significant collaborations with the Novo Nordisk Foundation, the Bill & Melinda Gates Foundation and others, enhancing our ability to tackle shared global health challenges effectively.
• Long-term impact: Our early investments in sensory neurons are now on the brink of revolutionising pain medicine, underscoring the value of curiosity-driven scientific funding with successful phase 3 trials.
• Global health advocacy: At COP28, we led efforts to spotlight the vital connection between health and climate change, placing health at the forefront of global discussions.
• Operational success: Despite economic challenges, our robust financial management has ensured strong returns and positioned us to seize future opportunities, continuing our relentless pursuit of improved health outcomes for all.